Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys

被引:86
作者
Mihara, M [1 ]
Kotoh, M
Nishimoto, N
Oda, Y
Kumagai, E
Takagi, N
Tsunemi, K
Ohsugi, Y
Kishimoto, T
Yoshizaki, K
Takeda, Y
机构
[1] Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka, Japan
[2] CSK Res Pk Inc, Nagano, Japan
[3] Osaka Univ, Sch Hlth & Sport Sci, Dept Med Sci 1, Osaka, Japan
关键词
anti-IL-6R antibody; monkey; collagen arthritis; treatment;
D O I
10.1006/clim.2000.4989
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the present study, we demonstrated the anti-arthritic effect of humanized anti-human IL-6 receptor (IL-6R) antibody, MRA, in cynomolgus monkey. MRA can react with monkey IL-6R and block signal transduction of IL-6, Collagen-induced arthritis (CIA) was induced by twice immunizing with bovine type II collagen (CII) emulsified with complete adjuvant, MRA was intravenously injected once a week, from the day of the first collagen immunization, for 13 weeks. The symptoms of arthritis were evaluated using a visual scoring system and radiography, Inflammatory parameters (C-reactive protein (CRP), fibrinogen, and erythrocyte sedimentation rate (ESR) and concentrations of anti-CII antibody, anti-MRA antibody, and MRA were monitored regularly. At the end of the study, histological evaluation was carried out. MRA, at a dose of 10 mg/kg, gave rise to statistically significant suppression. The elevation of serum CRP and fibrinogen levels and ESR were also inhibited. Furthermore, radiographic and histological examination showed that MRA treatment suppressed joint destruction. Our results demonstrate that IL-6 plays an important role in monkey CIA and that MRA may be an attractive agent for the treatment of rheumatoid arthritis. (C) 2001 Academic Press.
引用
收藏
页码:319 / 326
页数:8
相关论文
共 21 条
[1]   INTERLEUKIN-6 IN BIOLOGY AND MEDICINE [J].
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :1-78
[2]   Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis [J].
Campion, GV ;
Lebsack, ME ;
Lookabaugh, J ;
Gordon, G ;
Catalano, M ;
Borenstein, D ;
Caldwell, J ;
Cohen, SA ;
Cohen, SB ;
Fleischmann, R ;
Heller, MD ;
Howard, P ;
Jaffer, AM ;
Kaine, JL ;
Kitsis, E ;
Kopp, EJ ;
Moreland, LW ;
OHanlan, M ;
Prupas, M ;
Rosenberg, A ;
Rutstein, J ;
Sack, MR ;
Schiff, MH ;
Singleton, CM ;
Taborn, J ;
Tindall, E ;
Weaver, AL ;
Yocum, D .
ARTHRITIS AND RHEUMATISM, 1996, 39 (07) :1092-1101
[3]  
CATHCART ES, 1986, LAB INVEST, V54, P26
[4]   RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].
ELLIOTT, MJ ;
MAINI, RN ;
FELDMANN, M ;
KALDEN, JR ;
ANTONI, C ;
SMOLEN, JS ;
LEEB, B ;
BREEDVELD, FC ;
MACFARLANE, JD ;
BIJL, H ;
WOODY, JN .
LANCET, 1994, 344 (8930) :1105-1110
[5]   Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis [J].
Feldmann, M ;
Elliott, MJ ;
Woody, JN ;
Maini, RN .
ADVANCES IN IMMUNOLOGY, VOL 64, 1997, 64 :283-350
[6]   ADMINISTRATION OF INTERLEUKIN-12 IN COMBINATION WITH TYPE-II COLLAGEN INDUCES SEVERE ARTHRITIS IN DBA/1 MICE [J].
GERMANN, T ;
SZELIGA, J ;
HESS, H ;
STORKEL, S ;
PODLASKI, FJ ;
GATELY, MK ;
SCHMITT, E ;
RUDE, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) :4823-4827
[7]   EXCESSIVE PRODUCTION OF INTERLEUKIN-6/B CELL STIMULATORY FACTOR-II IN RHEUMATOID-ARTHRITIS [J].
HIRANO, T ;
MATSUDA, T ;
TURNER, M ;
MIYASAKA, N ;
BUCHAN, G ;
TANG, B ;
SATO, K ;
SHIMIZU, M ;
MAINI, R ;
FELDMAN, M ;
KISHIMOTO, T .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (11) :1797-1801
[8]   INTERLEUKIN-6 IN SYNOVIAL-FLUID AND SERUM OF PATIENTS WITH RHEUMATOID-ARTHRITIS AND OTHER INFLAMMATORY ARTHRITIDES [J].
HOUSSIAU, FA ;
DEVOGELAER, JP ;
VANDAMME, J ;
DEDEUXCHAISNES, CN ;
VANSNICK, J .
ARTHRITIS AND RHEUMATISM, 1988, 31 (06) :784-788
[9]   IL-6 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor [J].
Imazeki, I ;
Saito, H ;
Hasegawa, M ;
Shinkura, H ;
Kishimoto, T ;
Ohsugi, Y .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1998, 20 (07) :345-357
[10]   SERUM INTERLEUKIN-6 LEVELS IN RHEUMATOID-ARTHRITIS - CORRELATIONS WITH CLINICAL AND LABORATORY INDEXES OF DISEASE-ACTIVITY [J].
MADHOK, R ;
CRILLY, A ;
WATSON, J ;
CAPELL, HA .
ANNALS OF THE RHEUMATIC DISEASES, 1993, 52 (03) :232-234